A study to evaluate efficacy and safety of daprodustat compared to darbepoetin alfa in Japanese hemodialysis (HD)-dependent subjects with anemia associated with chronic kidney disease (CKD)

Trial Identifier: 201754
Sponsor: GlaxoSmithKline
Start Date: November 2016
Primary Completion Date: July 2018
Study Completion Date: July 2018

Available Languages

For questions about your Trial Results Summary, please see Sponsor contact section within your Trial Results Summary.

Language Description

Trial Locations

Country Location
Japan Aichi, Japan, 446-0053
Japan Aichi, Japan, 486-8510
Japan Aichi, Japan, 446-0065
Japan Aichi, Japan, 441-8023
Japan Aichi, Japan, 462-0802
Japan Aichi, Japan, 454-0932
Japan Aichi, Japan, 455-0021
Japan Chiba, Japan, 276-0031
Japan Ehime, Japan, 792-0812
Japan Ehime, Japan, 790-0962
Japan Fukui, Japan, 918-8503
Japan Fukuoka, Japan, 811-0213
Japan Fukuoka, Japan, 804-0094
Japan Fukuoka, Japan, 818-0083
Japan Fukuoka, Japan, 811-0120
Japan Fukushima, Japan, 963-8002
Japan Fukushima, Japan, 963-8071
Japan Gunma, Japan, 370-0615
Japan Gunma, Japan, 372-0817
Japan Gunma, Japan, 375-0024
Japan Hokkaido, Japan, 007-0803
Japan Hokkaido, Japan, 073-0196
Japan Hokkaido, Japan, 004-0814
Japan Hokkaido, Japan, 073-0022
Japan Ibaraki, Japan, 305-0861
Japan Ibaraki, Japan, 300-0062
Japan Ibaraki, Japan, 302-0011
Japan Kagawa, Japan, 761-8024
Japan Kanagawa, Japan, 234-0054
Japan Kanagawa, Japan, 224-0032
Japan Kanagawa, Japan, 235-0045
Japan Kanagawa, Japan, 227-0046
Japan Kyoto, Japan, 613-0034
Japan Miyagi, Japan, 981-0954
Japan Nagano, Japan, 390-1401
Japan Nagano, Japan, 399-8292
Japan Nagano, Japan, 390-0821
Japan Okayama, Japan, 714-0043
Japan Osaka, Japan, 543-0052
Japan Osaka, Japan, 594-0076
Japan Osaka, Japan, 584-0082
Japan Osaka, Japan, 547-0024
Japan Saitama, Japan, 348-0045
Japan Shizuoka, Japan, 424-0012
Japan Tokyo, Japan, 169-0075
Japan Tokyo, Japan, 158-0094
Japan Toyama, Japan, 930-0065
Japan Toyama, Japan, 938-8502
Japan Yamagata, Japan, 990-0834
Japan Yamaguchi, Japan, 755-0155